These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33098161)

  • 1. An effective hydroquinone alternative for topical skin lightening.
    Draelos ZD; Deliencourt-Godefroy G; Lopes L
    J Cosmet Dermatol; 2020 Dec; 19(12):3258-3261. PubMed ID: 33098161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.
    Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F
    J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone.
    Draelos ZD
    J Am Acad Dermatol; 2015 Jan; 72(1):105-7. PubMed ID: 25440437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency.
    Boissy RE; Visscher M; DeLong MA
    Exp Dermatol; 2005 Aug; 14(8):601-8. PubMed ID: 16026582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
    Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
    J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream.
    Grimes PE; McDaniel DH; Wortzman M; Nelson D
    J Drugs Dermatol; 2019 Jul; 18(7):642-648. PubMed ID: 31329402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.
    Draelos ZD; Yatskayer M; Bhushan P; Pillai S; Oresajo C
    Cutis; 2010 Sep; 86(3):153-8. PubMed ID: 21049734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of hydroquinone-free skin-lightening cream for photoaging.
    Dreher F; Draelos ZD; Gold MH; Goldman MP; Fabi SG; Puissegur Lupo ML
    J Cosmet Dermatol; 2013 Mar; 12(1):12-7. PubMed ID: 23438137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the safety of hydroquinone.
    Shivaram K; Edwards K; Mohammad TF
    Arch Dermatol Res; 2024 Jun; 316(7):378. PubMed ID: 38850450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
    Fabi SG; Goldman MP
    J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin lightening preparations and the hydroquinone controversy.
    Draelos ZD
    Dermatol Ther; 2007; 20(5):308-13. PubMed ID: 18045355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
    Serra M; Bohnert K; Narda M; Granger C; Sadick N
    J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent.
    Hamed SH; Sriwiriyanont P; deLong MA; Visscher MO; Wickett RR; Boissy RE
    J Cosmet Sci; 2006; 57(4):291-308. PubMed ID: 16957809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
    J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical benefit of a multimodal topical approach to treating skin dyspigmentation.
    Draelos ZD; Diaz I
    J Cosmet Dermatol; 2023 Jun; 22(6):1799-1804. PubMed ID: 37102219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrolysis of arbutin to hydroquinone by human skin bacteria and its effect on antioxidant activity.
    Bang SH; Han SJ; Kim DH
    J Cosmet Dermatol; 2008 Sep; 7(3):189-93. PubMed ID: 18789053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 2% deoxyarbutin and 4% hydroquinone as a depigmenting agent in healthy individuals: A double-blind randomized controlled clinical trial.
    Anwar AI; Asmarani Y; Madjid A; Patellongi I; Adriani A; As'ad S; Kurniadi I
    J Cosmet Dermatol; 2021 Dec; 20(12):3953-3959. PubMed ID: 33683782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone.
    Schlessinger J; Saxena S; Mohr S
    J Drugs Dermatol; 2016 Dec; 15(12):1571-1577. PubMed ID: 28095580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Topical treatment of pigmentation disorders with cosmetic and pharmaceutical agents].
    Kerscher M; Buntrock H
    Hautarzt; 2020 Dec; 71(12):944-949. PubMed ID: 33146766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations.
    Morag M; Nawrot J; Siatkowski I; Adamski Z; Fedorowicz T; Dawid-Pac R; Urbanska M; Nowak G
    J Cosmet Dermatol; 2015 Sep; 14(3):185-90. PubMed ID: 26119285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.